Twist Bioscience Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Twist Bioscience Corporation (TWST) on August 9, 2021, covering events that occurred on August 5, 2021. The filing reports significant corporate governance changes, specifically the appointment of a new director and a new principal accounting officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
- Board Appointment: Dr. Melissa Starovasnik was elected to the Board of Directors, effective August 5, 2021. She serves as a Class I director until the 2022 Annual Meeting.
- Officer Appointment: Kevin Yankton, previously the Chief Accounting Officer, was appointed as the Principal Accounting Officer, effective August 5, 2021. James Thorburn continues to serve as Chief Financial Officer and Principal Financial Officer.
Compensation and Management Commentary
Dr. Starovasnik's compensation package includes:
- A pro rata portion of the $40,000 annual cash retainer.
- Initial equity awards with an aggregate grant date fair value of $340,000, split equally between stock options and restricted stock units (RSUs). These vest one-third annually over three years.
- Eligibility for an annual RSU grant valued at $185,000 at the next annual meeting of stockholders.
Mr. Yankton brings extensive experience from Varex Imaging Corporation, Verifone, Inc., Cisco Systems, Inc., and PricewaterhouseCoopers LLP. He holds an MBA and is a Certified Public Accountant.
Investor Verification Checklist
- Verify Dr. Starovasnik's background and potential conflicts of interest via the attached press release (Exhibit 99.1).
- Confirm the vesting schedule and grant date fair value assumptions for the $340,000 initial equity award.
- Review the Company's 2018 Equity Incentive Plan to understand the terms of the annual $185,000 RSU grant.
- Monitor future filings for the impact of these leadership changes on financial reporting and strategic direction.